The Alzheimer's amyloid precursor protein (APP) can be processed via alternative pathways. The amyloidogenic pathway, which occurs normally in both neuronal and non-neuronal cells, leads to the production of A beta which is found deposited in plaques of AD (Alzheimer's disease) patients. Stimulation of the non-amyloidogenic pathway, in which APP is cleaved within A beta, can be brought about via activation of protein kinase C or inhibition of protein phosphatase 1. These observations may represent first leads towards therapeutic strategies for AD. The current application proposes to extend these findings by addressing the following questions: 1) which isoforms of the protein kinases and phosphatases are responsible for regulating APP processing and A beta formation; 2) what are the effects of modulating net phosphorylation on APP expression and processing in the living brain; and, 3) what are the biological consequences of stimulating APP secretion via increasing net phosphorylation. Understanding the normal and pathological metabolism of APP, as well as the biological effects of regulating APP processing, could advance rational therapeutic strategies for APP. The long-term objective, and health-relatedness, of the proposal is discovering new avenues for the rational design of therapies for AD directed at altering APP processing and/or A beta accumulation. The techniques to be used include molecular biological, cell biological and biochemical techniques.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG009464-10
Application #
6325703
Study Section
Project Start
2000-07-01
Project End
2001-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
10
Fiscal Year
2000
Total Cost
$241,580
Indirect Cost
Name
Rockefeller University
Department
Type
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Bettayeb, Karima; Hooli, Basaraj V; Parrado, Antonio R et al. (2016) Relevance of the COPI complex for Alzheimer's disease progression in vivo. Proc Natl Acad Sci U S A 113:5418-23
Bettayeb, Karima; Chang, Jerry C; Luo, Wenjie et al. (2016) ?-COP modulates A? peptide formation via retrograde trafficking of APP. Proc Natl Acad Sci U S A 113:5412-7
Liebmann, Thomas; Renier, Nicolas; Bettayeb, Karima et al. (2016) Three-Dimensional Study of Alzheimer's Disease Hallmarks Using the iDISCO Clearing Method. Cell Rep 16:1138-1152
Ceglia, Ilaria; Reitz, Christiane; Gresack, Jodi et al. (2015) APP intracellular domain-WAVE1 pathway reduces amyloid-? production. Nat Med 21:1054-9
Tian, Yuan; Chang, Jerry C; Greengard, Paul et al. (2014) The convergence of endosomal and autophagosomal pathways: implications for APP-CTF degradation. Autophagy 10:694-6
Chiba, Kyoko; Araseki, Masahiko; Nozawa, Keisuke et al. (2014) Quantitative analysis of APP axonal transport in neurons: role of JIP1 in enhanced APP anterograde transport. Mol Biol Cell 25:3569-80
Hochard, Arnaud; Oumata, Nassima; Bettayeb, Karima et al. (2013) Aftins increase amyloid-?42, lower amyloid-?38, and do not alter amyloid-?40 extracellular production in vitro: toward a chemical model of Alzheimer's disease? J Alzheimers Dis 35:107-20
Tian, Yuan; Chang, Jerry C; Fan, Emily Y et al. (2013) Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy. Proc Natl Acad Sci U S A 110:17071-6
Oh, Yong-Seok; Gao, Pu; Lee, Ko-Woon et al. (2013) SMARCA3, a chromatin-remodeling factor, is required for p11-dependent antidepressant action. Cell 152:831-43
Bettayeb, Karima; Oumata, Nassima; Zhang, Yuanyuan et al. (2012) Small-molecule inducers of Aýý-42 peptide production share a common mechanism of action. FASEB J 26:5115-23

Showing the most recent 10 out of 115 publications